Genetic Analysis subsequent offering to existing shareholders has now been registered with the Norwegian Register of Business Enterprises

Genetic Analysis AS' (“GA” or the “Company”) subsequent offering to existing shareholders, for which the subscription period ended on December 22, 2023 (the "Subsequent Offering"), has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).

During the period December 11 – December 22, 2023, GA carried out the Subsequent Offering that provided the Company with approximately NOK 3.1 million by issuance of 3,958,036 new shares, before issue costs. The Subsequent Offering has now been registered with the Norwegian Register of Business Enterprises.

After this, the Company's new registered share capital is NOK 25,294,413 divided into 42,157,355 shares, each with a nominal value of NOK 0.60.

Advisors

In connection with the Subsequent Offering, Sedermera Corporate Finance AB (www.sedermera.se) is appointed Swedish financial advisor and Advokatfirmaet Wiersholm AS is the Company's Norwegian legal advisor.

For further information, please contact:

Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com

Eilert Aamodt, Chief Financial Officer
E-mail: ea@genetic-analysis.com

About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.

For more general information: www.genetic-analysis.com

Stay updated on GA and sign up for more investor-related information: https://www.genetic-analysis.com/subscriptions/

Interested in reading more about GA's products? Please visit ga-map.com